Your session is about to expire
← Back to Search
Other
ALTO-300 in Depression
Phase 2
Waitlist Available
Research Sponsored by Alto Neuroscience
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up measured 6 times over 8 weeks
Awards & highlights
No Placebo-Only Group
Summary
This trial studies ALTO-300, a treatment, to understand its effects on various patients. Researchers aim to find indicators that show how effective ALTO-300 is.
Eligible Conditions
- Depression
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ measured 6 times over 8 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~measured 6 times over 8 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
To evaluate the safety of ALTO-300
To understand the relationship between baseline biology and clinical outcome to ALTO-300 using the Clinical Global Impression scale - Severity (CGI-S)
To understand the relationship between baseline biology and clinical outcome to ALTO-300 using the Montgomery-Åsberg Depression Rating Scale (MADRS)
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: ALTO-300Experimental Treatment1 Intervention
ALTO-300 oral (PO) tablet; daily dosing 8 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ALTO-300 oral (PO) tablet
2021
Completed Phase 2
~100
Find a Location
Who is running the clinical trial?
Alto NeuroscienceLead Sponsor
10 Previous Clinical Trials
1,247 Total Patients Enrolled
9 Trials studying Depression
1,175 Patients Enrolled for Depression